|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
EPFL Innovation Park, Bâtiment B, Lausanne, Vaud CH-1015, CH
|
|
Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s Disease, Alzheimer’s disease and related disorders.
Asceneuron is a privately held company financed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Kurma Partners. For more information, please visit www.asceneuron.com.
Further information: www.asceneuron.com
|
Asceneuron SA Email Formats | Example Email Formats | Percentage |
---|---|---|
{first}.{last} | [email protected] |
100%
|
The widely used Asceneuron SA email format is {first}.{last} (e.g. [email protected]) with 100% adoption across the company.
To contact Asceneuron SA customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.